caa a22 4500 606184384 CHVBK 20210128100826.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s00405-014-3398-3 doi (NATIONALLICENCE)springer-10.1007/s00405-014-3398-3 The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2 [Elektronische Daten] [Mikkel Alanin, Camilla Klausen, Per Caye-Thomasen, Carsten Thomsen, Kaare Fugleholm, Lars Poulsgaard, Ulrik Lassen, Morten Mau-Sorensen, Kenneth Hofland] The hallmark of neurofibromatosis type 2 (NF2) is bilateral vestibular schwannomas (VS) and severe hearing loss is common in NF2 patients. Vascular endothelial growth factor (VEGF) expression level in NF2 correlates with tumour growth rate and bevacizumab, a VEGF-binding antibody, has previously been shown to induce tumour shrinkage and improve hearing. We retrospectively reviewed the effect of bevacizumab on hearing and VS tumour size in 12 consecutive NF2 patients. Bevacizumab 10mg/kg was administered intravenously every second week for 6months; hereafter, bevacizumab 15mg/kg was administered every third week. Patients were evaluated with repeated audiometries, MR scans and clinical evaluations. Radiological response was defined as a 20% or greater reduction in VS volume. A total of 398 treatments (median 36) were administered and the median duration on therapy was 22months (range 7-34). We observed a radiological response (≥20% tumour shrinkage) in seven out of 18 tumours (39%) in six out of 12 patients (50%). Sustained radiological responses were maintained in six tumours (33%) for more than 2months. Three patients had objectively improved hearing and five patients reported subjective benefit in neurological symptoms, including improved hearing. Toxicity was in general manageable; however, one patient died from cerebral haemorrhage which was possibly related to therapy. In conclusion, bevacizumab improved hearing and reduced the size of VS in some patients with progressive NF2 which corroborates previous findings; however, the risk of severe side effects should be carefully considered and discussed with the patients prior to treatment. Springer-Verlag Berlin Heidelberg, 2014 NF2 nationallicence Bevacizumab nationallicence Avastin nationallicence Vestibular schwannoma nationallicence Alanin Mikkel Department of Otolaryngology-Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Klausen Camilla Department of Radiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Caye-Thomasen Per Department of Otolaryngology-Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Thomsen Carsten Department of Radiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Fugleholm Kaare Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Poulsgaard Lars Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Lassen Ulrik Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Mau-Sorensen Morten Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut Hofland Kenneth Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/12(2015-12-01), 3627-3633 0937-4477 272:12<3627 2015 272 405 https://doi.org/10.1007/s00405-014-3398-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00405-014-3398-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Alanin Mikkel Department of Otolaryngology-Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Klausen Camilla Department of Radiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Caye-Thomasen Per Department of Otolaryngology-Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Thomsen Carsten Department of Radiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Fugleholm Kaare Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Poulsgaard Lars Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Lassen Ulrik Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Mau-Sorensen Morten Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Hofland Kenneth Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark aut NATIONALLICENCE 773 0- European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/12(2015-12-01), 3627-3633 0937-4477 272:12<3627 2015 272 405